131 related articles for article (PubMed ID: 36638694)
1. Risk of depressive disorders associated with medical cannabis authorization: A propensity score matched cohort study.
Yana JL; Lee C; Eurich DT; Dyck JRB; Hanlon JG; Zongo A
Psychiatry Res; 2023 Feb; 320():115047. PubMed ID: 36638694
[TBL] [Abstract][Full Text] [Related]
2. Medical cannabis authorization and risk of emergency department visits and hospitalization due to psychotic disorders: A propensity score-matched cohort study.
Dubois C; Lunghi C; Eurich DT; Dyck JRB; Hyshka E; Hanlon JG; Zongo A
Schizophr Res; 2024 Feb; 264():534-542. PubMed ID: 38330686
[TBL] [Abstract][Full Text] [Related]
3. Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study.
Zongo A; Lee C; Dyck JRB; El-Mourad J; Hyshka E; Hanlon JG; Eurich DT
BMC Cardiovasc Disord; 2021 Sep; 21(1):426. PubMed ID: 34507536
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Predictors of Cannabis-Related Poisoning and Mental and Behavioral Disorders among Patients with Medical Cannabis Authorization: A Cohort Study.
Zongo A; Lee C; Dyck JRB; El-Mourad J; Hyshka E; Hanlon JG; Eurich DT
Subst Use Misuse; 2022; 57(10):1633-1641. PubMed ID: 35866679
[TBL] [Abstract][Full Text] [Related]
5. Substance Use Disorders and Psychoactive Drug Poisoning in Medically Authorized Cannabis Patients: Longitudinal Cohort Study.
Zongo A; Lee C; El-Mourad J; Dyck JRB; Hyshka E; Hanlon JG; Eurich DT
Can J Psychiatry; 2022 Jul; 67(7):544-552. PubMed ID: 34806435
[TBL] [Abstract][Full Text] [Related]
6. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study.
Blanco C; Hasin DS; Wall MM; Flórez-Salamanca L; Hoertel N; Wang S; Kerridge BT; Olfson M
JAMA Psychiatry; 2016 Apr; 73(4):388-95. PubMed ID: 26886046
[TBL] [Abstract][Full Text] [Related]
7. Association of Cannabis Use With Self-harm and Mortality Risk Among Youths With Mood Disorders.
Fontanella CA; Steelesmith DL; Brock G; Bridge JA; Campo JV; Fristad MA
JAMA Pediatr; 2021 Apr; 175(4):377-384. PubMed ID: 33464286
[TBL] [Abstract][Full Text] [Related]
8. Cohort study of medical cannabis authorisation and healthcare utilisation in 2014-2017 in Ontario, Canada.
Eurich D; Lee C; Zongo A; Minhas-Sandhu JK; Hanlon JG; Hyshka E; Dyck J
J Epidemiol Community Health; 2020 Mar; 74(3):299-304. PubMed ID: 31831619
[TBL] [Abstract][Full Text] [Related]
9. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna J; Patterson B; Van Ameringen M
Depress Anxiety; 2017 Nov; 34(11):1006-1017. PubMed ID: 28636769
[TBL] [Abstract][Full Text] [Related]
10. Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada.
Dubois C; Fernandes H; Lin M; Martins KJB; Dyck JRB; Klarenbach SW; Richer L; Jess E; Hanlon JG; Hyshka E; Eurich DT
BMC Public Health; 2024 Mar; 24(1):859. PubMed ID: 38504198
[TBL] [Abstract][Full Text] [Related]
11. Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014-2017 in Ontario, Canada.
Lee C; Voaklander D; Minhas-Sandhu JK; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
Inj Epidemiol; 2021 Apr; 8(1):33. PubMed ID: 33906699
[TBL] [Abstract][Full Text] [Related]
12. Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study.
Myran DT; Harrison LD; Pugliese M; Tanuseputro P; Gaudreault A; Fiedorowicz JG; Solmi M
EClinicalMedicine; 2024 Mar; 69():102455. PubMed ID: 38544799
[TBL] [Abstract][Full Text] [Related]
13. Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users.
Turna J; Simpson W; Patterson B; Lucas P; Van Ameringen M
J Psychiatr Res; 2019 Apr; 111():134-139. PubMed ID: 30738930
[TBL] [Abstract][Full Text] [Related]
14. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood.
Degenhardt L; Coffey C; Romaniuk H; Swift W; Carlin JB; Hall WD; Patton GC
Addiction; 2013 Jan; 108(1):124-33. PubMed ID: 22775447
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Medical Cannabis and Health-Related Quality of Life.
Arkell TR; Downey LA; Hayley AC; Roth S
JAMA Netw Open; 2023 May; 6(5):e2312522. PubMed ID: 37159196
[TBL] [Abstract][Full Text] [Related]
16. Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada.
Lee C; Lin M; Martins KJB; Dyck JRB; Klarenbach S; Richer L; Jess E; Hanlon JG; Hyshka E; Eurich DT
BMC Public Health; 2021 May; 21(1):843. PubMed ID: 33933061
[TBL] [Abstract][Full Text] [Related]
17. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis.
Round JM; Lee C; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
BMC Public Health; 2020 Jun; 20(1):987. PubMed ID: 32576158
[TBL] [Abstract][Full Text] [Related]
18. [Comorbidity in 207 cannabis users in a specific outpatient setting].
Guillem E; Arbabzadeh-Bouchez S; Vorspan F; Bellivier F
Encephale; 2015 Jun; 41 Suppl 1():S7-12. PubMed ID: 25123065
[TBL] [Abstract][Full Text] [Related]
19. Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.
Lee C; Round JM; Klarenbach S; Hanlon JG; Hyshka E; Dyck JRB; Eurich DT
Harm Reduct J; 2021 Jun; 18(1):61. PubMed ID: 34103058
[TBL] [Abstract][Full Text] [Related]
20. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review.
Baker AL; Hides L; Lubman DI
J Clin Psychiatry; 2010 Mar; 71(3):247-54. PubMed ID: 20331929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
